Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)

NCT04113863 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT04113863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04113863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Terminated
Start date
June 18, 2019
Completion date
January 30, 2025
Enrollment
76 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm female